Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

This study reports that the dye peri-xanthenoxanthene (PXX) can act as an efficient photocatalyst for various radical reactions, including complex dual catalytic processes and the synthesis of an investigational drug intermediate.

This review discusses prevention, diagnosis, and treatment strategies for traction alopecia but presents no new clinical findings; the authors emphasize early intervention to prevent permanent hair loss.

In this article, two case studies of hair tourniquets around digits are discussed, highlighting the condition's potential causes and management strategies, and emphasizing the role of midwives and health visitors in educating expectant mothers to minimize the risk to children.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This study describes tumor necrosis factor inhibitor-associated psoriatic alopecia, highlighting the distinctive histologic feature of sebaceous lobule atrophy, which is potentially reversible and helps differentiate it from idiopathic psoriatic alopecia.

Taxane chemotherapy can cause permanent hair loss by damaging hair follicles and altering their DNA.

This review guides readers on how to critically evaluate multiple treatment comparison meta-analyses, offering insights for interpreting and communicating these studies but reporting no new results.

This study found that traction alopecia risk was higher in adults than children and increased further when traction was combined with chemically relaxed hair.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This report introduces Barcelona - TrichoScan as a novel software tool purported to effectively analyze hair growth in patients with androgenetic alopecia or androgenetic effluvium, but it provides no clinical data.

This report suggests a possible association between temporal triangular alopecia and sebaceous nevus, and identifies a pinkish background as a new trichoscopic finding for TTA.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

This report from Tangle Teezer and TRI Princeton indicates that their Extra Gentle brush reduces hair breakage by up to 39%, offering a therapeutic experience for users with fragile scalps.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

In this case report, researchers observed that two sisters with congenital immune disorders experienced partial hair regrowth while receiving tofacitinib for severe alopecia areata, highlighting the need for careful clinical and laboratory monitoring due to potential infection risks associated with JAK inhibitor therapy.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

Tofacitinib may effectively treat folliculitis decalvans.

In this study, Wood's lamp effectively identified tinea capitis among pediatric patients with alopecia, particularly when contact with animals was a factor, supporting its diagnostic use in primary healthcare settings.

This study found that fifteen days of Trataka practice significantly reduced menopausal symptoms among participating women compared to a control group.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This study provides ex vivo proof-of-principle that low-intensity ultrasound may protect human hair follicles from paclitaxel-induced damage, potentially reducing chemotherapy-related alopecia.

This case report describes a 53-year-old woman with a rare presentation of trichostasis spinulosa on her breast and abdomen, featuring itchy, comedo-like lesions. Dermoscopy revealed diagnostic features that may eliminate the need for a biopsy, highlighting the potential for non-invasive diagnosis in such cases.

In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.